Server: Microsoft-IIS/3.0 Date: Thu, 18 Dec 1997 17:56:45 GMT Content-Type: text/html Accept-Ranges: bytes Last-Modified: Wed, 12 Nov 1997 19:10:06 GMT Content-Length: 3843 NTI Press Releases

Recent Press Releases

Neurobiological Technologies, Inc. Completes Enrollment in Phase II Trial for Neuropathic Pain

Neurobiological Technologies, Inc. Announces First Quarter Results

Neurobiological Technologies, Inc. Announces Fiscal Year End Results

Neurobiological Technologies, Inc. Starts Phase II Xerecept™ Trial; Potential Treatment for Patients with Brain Tumors

Neurobiological Technologies, Inc. Executive Vice President Resigns

Neurobiological Technologies, Inc. Applies for Orphan Drug Status of Xerecept™

Neurobiological Technologies, Inc. Files IND for Xerecept™

Neurobiological Technologies, Inc. Xerecept™ (CRF) Results Presented At 10th Annual Symposium On Intracranial Pressure

Neurobiological Technologies Reports Third Quarter Results

Neurobiological Technologies, Inc. Elects Veteran Pharmaceutical Executive to Positions of President and CEO

Neurobiological Technologies, Inc. Starts Phase II Memantine Trial

Neurobiological Technologies, Inc. Announces Resignation of Director and Stock Purchases by Insiders

Paul Freiman and Abraham Sofaer Join Board of Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. Announces Second Quarter Results

Neurobiological Technologies, Inc. Announces Results of Rheumatoid Arthritis Trial

Neurobiological Technologies, Inc. Starts Phase II Memantine Trial with NIH AIDS Unit

NTII Initiates Neuroprotection Research Program with Children's Hospital in Boston

 

Profile | Pipeline | Financial | Stock Info | Neuroprotection | Press Releases | Glossary | Contacts